title: Drug maker's efforts to compete in lucrative insulin market are under scrutiny.
authors.forename: Gardiner
authors.initials: G
authors.lastname: Harris
authors.forename: Robert
authors.initials: R
authors.lastname: Pear
mesh_terms: D004345:Drug Industry / Q000191:economics* / Q000941:ethics / Q000331:legislation & jurisprudence*; D035082:Federal Government; D005607:Fraud / Q000331:legislation & jurisprudence; D006801:Humans; D007328:Insulin / Q000191:economics*; D040541:Marketing / Q000191:economics / Q000941:ethics*; D010594:Pharmacies / Q000191:economics* / Q000941:ethics; D010595:Pharmacists / Q000191:economics* / Q000941:ethics; D010823:Physician Assistants / Q000191:economics* / Q000941:ethics; D013219:State Government; D014481:United States
chemical_list: D007328:Insulin